Ratings by Stifel (Laura Prendergast)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/15/2026 | Cogent | COGT | Maintain | Buy (Buy) |
|
Details | ||
| 6/11/2026 | ORIC Pharmaceuticals | ORIC | New Coverage | Buy (N/A) |
7.54 (10.73) |
42.31% | Details | |
| 6/9/2026 | Nuvalent | NUVL | Downgrade | Hold (Buy) |
88.49 (123.96) |
40.08% | Details | |
| 6/1/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 6/1/2026 | Nuvalent | NUVL | Maintain | Buy (Buy) |
|
Details | ||
| 6/1/2026 | Cogent | COGT | Maintain | Buy (Buy) |
|
Details | ||
| 5/22/2026 | Black Diamond Therapeutics | BDTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2026 | Foghorn Therapeutics | FHTX | Maintain | Buy (Buy) |
|
Details | ||
| 4/27/2026 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (N/A) |
|
Details | ||
| 4/20/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (N/A) |
|
Details | ||
| 4/20/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 4/7/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 3/31/2026 | Nuvalent | NUVL | Maintain | Buy (Buy) |
|
Details | ||
| 3/16/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2026 | Erasca Inc | ERAS | Maintain | Buy (Buy) |
|
Details | ||
| 3/12/2026 | Foghorn Therapeutics | FHTX | Maintain | Buy (Buy) |
|
Details | ||
| 3/10/2026 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (Buy) |
|
Details | ||
| 3/6/2026 | BridgeBio Oncology Therapeutics, In | BBOT | Maintain | Buy (Buy) |
|
Details | ||
| 3/5/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
24.95 (11.47) |
-54.03% | Details | |
| 2/10/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Buy (N/A) |
10.68 (8.56) |
-19.85% | Details | |
| 2/9/2026 | Erasca Inc | ERAS | Maintain | Buy (Buy) |
|
Details | ||
| 1/22/2026 | Cogent | COGT | Maintain | Buy (N/A) |
|
Details | ||
| 1/21/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 1/12/2026 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 1/12/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (Buy) |
|
Details | ||
| 1/12/2026 | Foghorn Therapeutics | FHTX | Maintain | Buy (Buy) |
|
Details | ||
| 1/8/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 12/8/2025 | Cogent | COGT | Maintain | Buy (Buy) |
|
Details | ||
| 12/4/2025 | Black Diamond Therapeutics | BDTX | Maintain | Buy (Buy) |
|
Details | ||
| 12/4/2025 | Foghorn Therapeutics | FHTX | New Coverage | Buy (N/A) |
4.29 (5.19) |
20.98% | Details | |
| 12/4/2025 | Tango Therapeutics Inc. | TNGX | New Coverage | Buy (N/A) |
10.08 (28.56) |
183.33% | Details | |
| 11/17/2025 | Nuvalent | NUVL | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2025 | Erasca Inc | ERAS | Maintain | Buy (Buy) |
|
Details | ||
| 11/10/2025 | Cogent | COGT | Upgrade | Buy (Hold) |
14.82 (39.08) |
163.7% | Details | |
| 11/10/2025 | Cogent | COGT | Maintain | Hold (Hold) |
|
Details | ||
| 11/6/2025 | Erasca Inc | ERAS | Maintain | Buy (N/A) |
|
Details | ||
| 10/16/2025 | Cogent | COGT | New Coverage | Hold (N/A) |
15.43 (14.82) |
-3.95% | Details | |
| 10/16/2025 | Erasca Inc | ERAS | New Coverage | Buy (N/A) |
2.41 (19.17) |
695.44% | Details | |
| 10/16/2025 | Revolution | RVMD | New Coverage | Buy (N/A) |
47.50 (186.16) |
291.92% | Details | |
| 10/16/2025 | Black Diamond Therapeutics | BDTX | New Coverage | Buy (N/A) |
3.76 (1.79) |
-52.39% | Details | |
| 10/16/2025 | Nuvalent | NUVL | New Coverage | Buy (N/A) |
84.66 (88.49) |
4.52% | Details |
